Crinetics Pharmaceuticals, Inc.
CRNX
Hisse Senetlerindeki Sıralama
#2197
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Hisse Fiyatı
$84.95
Son senkronizasyon: 2026-09-01
Piyasa Değeri
$9.00B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
110.12%
Ülke
US
Ticaret Crinetics Pharmaceuticals, Inc. (CRNX)
Kategori
Healthcare
Crinetics Pharmaceuticals, Inc. (CRNX) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $84.95 - 2026-09-01
Gün sonu en düşük fiyat: $24.52 - 2018-07-01
Gün sonu en düşük fiyat: $24.52 - 2018-07-01
Crinetics Pharmaceuticals, Inc. için hisse fiyatı geçmişi: 2018 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | 3.89% |
| 2025 | -13.25% |
| 2024 | 59.38% |
| 2023 | 103.03% |
| 2022 | -34.46% |
| 2021 | 91.75% |
| 2020 | -37.94% |
| 2019 | -30.68% |
| 2018 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $536.91 | 25.90% |
US
|
|
| $230.20 | 757.36% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $892.44 | 9.61% |
NL
|
